Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Weird homes

Home is where the heart is, no matter what unusual form that home may take.  Slideshow 

Photo

The drone wars

The frontlines of America's covert drone program.  Slideshow 

Sponsored Links

U.S. to spend another $1 billion on flu vaccine

Related News

A technician works in the inoculation area during preparations to produce vaccines for the H1N1 flu virus at a lab in Wuhan, Hubei province June 17, 2009. REUTERS/China Daily

A technician works in the inoculation area during preparations to produce vaccines for the H1N1 flu virus at a lab in Wuhan, Hubei province June 17, 2009.

Credit: Reuters/China Daily

WASHINGTON | Mon Jul 13, 2009 8:38am EDT

WASHINGTON (Reuters) - The United States will spend another $1 billion on ingredients for an H1N1 vaccine, U.S. Health and Human Services Secretary Kathleen Sebelius said on Sunday.

"There'll be another $1 billion worth of orders placed to get the bulk ingredients for an H1N1 vaccination. Congress has agreed with the president that this is the number one priority, keeping Americans safe and secure," Sebelius said on CNN.

Sebelius has said plans were on track for a mid-October vaccination program, although it was not certain Americans would be offered the vaccine for the so-called swine flu.

"We are aggressively working on, first of all, testing the virus strains to get a vaccination ready. It needs to be safe so testing and clinical trials will start this month. We'll know a lot more by the end of the summer and it needs to be effective," she said.

The World Health Organization may issue guidance as soon as Monday on whether an H1N1 swine flu vaccine will be offered alongside the seasonal flu vaccine.

Vaccine makers Sanofi-Aventis, Novartis, Baxter, GlaxoSmithKline, Solvay and AstraZeneca's MedImmune subsidiary have finished making seasonal flu vaccines for this year.

The U.S. Food and Drug Administration has scheduled a July 23 advisory panel meeting to discuss clinical trials of the vaccines against the H1N1 influenza virus and the U.S. Advisory Committee on Immunization Practice wills meet July 29.

"FDA is working with the scientists at NIH (National Institutes of Health) to make sure that we have a safe and effective strain and then we're getting ready to make sure that we have a vaccination program," Sebelius said.

Health experts estimate at least 1 million people have been infected with H1N1 in the United States, and the U.S. Centers for Disease Control and Prevention has confirmed 211 deaths. It often takes weeks or months to collect data on flu deaths.

About 36,000 people die each year from the seasonal flu in the United States alone, and 250,000 to 500,000 die globally.

(Editing by Maggie Fox)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.